Real-World Treatment Patterns and Physician Preferences for Biologics in Moderate-to-Severe Inflammatory Bowel Disease: Retrospective Chart Review in Europe.

Lynn HuynhSteve HassLaurent Peyrin-BirouletMei Sheng DuhHeather SipsmaMu ChengAngie LaxArpita Nag

Published in: Crohn's & colitis 360 (2022)

Infliximab and adalimumab originators dominated first-line biologic therapy for moderate-to-severe UC and CD. Understanding real-world treatment patterns can help assess new treatment uptake and suggest opportunities for improving treatment.

Keyphrases

rheumatoid arthritis
emergency department
high intensity
cross sectional
ulcerative colitis
drug induced
juvenile idiopathic arthritis
decision making